vs
Curbline Properties Corp.(CURB)与RECURSION PHARMACEUTICALS, INC.(RXRX)财务数据对比。点击上方公司名可切换其他公司
Curbline Properties Corp.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.5倍($54.1M vs $35.5M),Curbline Properties Corp.净利率更高(17.6% vs -304.2%,领先321.9%)
Recursion Pharmaceuticals是一家临床阶段生物技术企业,依托人工智能技术和高通量生物实验体系,开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法,核心市场覆盖北美,与全球多家生物制药企业合作推进在研管线落地。
CURB vs RXRX — 直观对比
营收规模更大
CURB
是对方的1.5倍
$35.5M
净利率更高
CURB
高出321.9%
-304.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $54.1M | $35.5M |
| 净利润 | $9.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 17.8% | -304.8% |
| 净利率 | 17.6% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益(稀释后) | $0.08 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
CURB
RXRX
| Q4 25 | $54.1M | $35.5M | ||
| Q3 25 | $48.6M | $5.2M | ||
| Q2 25 | $41.4M | $19.2M | ||
| Q1 25 | $38.7M | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $29.8M | $26.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $13.8M |
净利润
CURB
RXRX
| Q4 25 | $9.6M | $-108.1M | ||
| Q3 25 | $9.4M | $-162.3M | ||
| Q2 25 | $10.4M | $-171.9M | ||
| Q1 25 | $10.6M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $-15.4M | $-95.8M | ||
| Q2 24 | — | $-97.5M | ||
| Q1 24 | — | $-91.4M |
毛利率
CURB
RXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率
CURB
RXRX
| Q4 25 | 17.8% | -304.8% | ||
| Q3 25 | 19.3% | -3327.6% | ||
| Q2 25 | 25.3% | -916.8% | ||
| Q1 25 | 27.6% | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | -51.8% | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率
CURB
RXRX
| Q4 25 | 17.6% | -304.2% | ||
| Q3 25 | 19.2% | -3135.3% | ||
| Q2 25 | 25.1% | -894.2% | ||
| Q1 25 | 27.3% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | -51.8% | -367.5% | ||
| Q2 24 | — | -676.6% | ||
| Q1 24 | — | -662.4% |
每股收益(稀释后)
CURB
RXRX
| Q4 25 | $0.08 | $-0.17 | ||
| Q3 25 | $0.09 | $-0.36 | ||
| Q2 25 | $0.10 | $-0.41 | ||
| Q1 25 | $0.10 | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | $-0.15 | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $289.6M | $743.3M |
| 总债务越低越好 | $423.2M | $9.6M |
| 股东权益账面价值 | $1.9B | $1.1B |
| 总资产 | $2.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.22× | 0.01× |
8季度趋势,按日历期对齐
现金及短期投资
CURB
RXRX
| Q4 25 | $289.6M | $743.3M | ||
| Q3 25 | $430.1M | $659.8M | ||
| Q2 25 | $429.9M | $525.1M | ||
| Q1 25 | $594.0M | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | $2.5M | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务
CURB
RXRX
| Q4 25 | $423.2M | $9.6M | ||
| Q3 25 | $396.4M | $11.9M | ||
| Q2 25 | $99.1M | $14.2M | ||
| Q1 25 | $99.0M | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益
CURB
RXRX
| Q4 25 | $1.9B | $1.1B | ||
| Q3 25 | $1.9B | $1.0B | ||
| Q2 25 | $1.9B | $919.1M | ||
| Q1 25 | $1.9B | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $1.1B | $524.6M | ||
| Q2 24 | — | $584.4M | ||
| Q1 24 | — | $401.2M |
总资产
CURB
RXRX
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $1.2B | $726.5M | ||
| Q2 24 | — | $775.9M | ||
| Q1 24 | — | $557.8M |
负债/权益比
CURB
RXRX
| Q4 25 | 0.22× | 0.01× | ||
| Q3 25 | 0.21× | 0.01× | ||
| Q2 25 | 0.05× | 0.02× | ||
| Q1 25 | 0.05× | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $124.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 13.04× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势,按日历期对齐
经营现金流
CURB
RXRX
| Q4 25 | $124.6M | $-46.1M | ||
| Q3 25 | $39.2M | $-117.4M | ||
| Q2 25 | $34.2M | $-76.4M | ||
| Q1 25 | $25.4M | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | — | $-82.2M | ||
| Q1 24 | — | $-102.3M |
自由现金流
CURB
RXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率
CURB
RXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度
CURB
RXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率
CURB
RXRX
| Q4 25 | 13.04× | — | ||
| Q3 25 | 4.19× | — | ||
| Q2 25 | 3.28× | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图